Frankfurt - Delayed Quote • EUR Veracyte, Inc. (12V.F) Follow 18.10 -0.20 (-1.09%) At close: April 26 at 8:01 AM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for 12V.F 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 12V.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 What Makes Veracyte (VCYT) a Lucrative Investment? Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines 7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff Veracyte Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands Q4 2023 Veracyte Inc Earnings Call Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook Related Tickers ALEC Alector, Inc. 5.25 +9.15% ARCT Arcturus Therapeutics Holdings Inc. 26.55 +1.45% SGMO Sangamo Therapeutics, Inc. 0.5178 +2.94% BEAM Beam Therapeutics Inc. 21.38 -1.02% EDIT Editas Medicine, Inc. 5.32 +1.92%
